Pulse Biosciences, Inc. (PLSE)

NASDAQ: PLSE · IEX Real-Time Price · USD
6.35
-0.05 (-0.78%)
Jun 5, 2023, 12:38 PM EDT - Market open
-0.78%
Market Cap 304.50M
Revenue (ttm) 256,000
Net Income (ttm) -51.03M
Shares Out 47.62M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,497
Open 6.30
Previous Close 6.40
Day's Range 6.20 - 6.44
52-Week Range 1.18 - 9.69
Beta 1.14
Analysts Hold
Price Target n/a
Earnings Date May 11, 2023

About PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 201... [Read more]

Sector Healthcare
IPO Date May 18, 2016
Employees 61
Stock Exchange NASDAQ
Ticker Symbol PLSE
Full Company Profile

Financial Performance

In 2022, PLSE's revenue was $700,000, a decrease of -50.63% compared to the previous year's $1.42 million. Losses were -$58.51 million, -8.10% less than in 2021.

Financial Statements

News

Pulse Biosciences' Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial...

2 weeks ago - Business Wire

Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atria...

3 weeks ago - Business Wire

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atria...

3 weeks ago - Business Wire
}

Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA...

1 month ago - Business Wire

Pulse Biosciences Announces $65 Million Private Placement

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology and proprietary CellFX Sys...

1 month ago - Business Wire

Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and ...

1 month ago - Business Wire

Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and ...

2 months ago - Business Wire

Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and ...

3 months ago - Business Wire
}

Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology an...

4 months ago - Business Wire

Pulse Biosciences Reports Third Quarter 2022 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company and creator of the unique CellFX® System which harnesses and effectively controls the a...

7 months ago - Business Wire

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

8 months ago - Business Wire

Pulse Biosciences Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today...

9 months ago - Business Wire
}

Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

9 months ago - Business Wire

Pulse Biosciences Reports Second Quarter 2022 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

10 months ago - Business Wire

Pulse Biosciences Receives FDA 510(k) Clearance of Expanded Energy Settings for use with the CellFX® System

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

10 months ago - Business Wire

Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

11 months ago - Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

1 year ago - Business Wire

Pulse Biosciences, Inc. Announces the Closing of Its Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano...

1 year ago - Business Wire

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano...

1 year ago - Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contact the Firm

1 year ago - Business Wire

Pulse Biosciences, Inc. Announces Changes to its Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System Powered by Nano...

1 year ago - Business Wire

Pulse Biosciences Reports First Quarter 2022 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

1 year ago - Business Wire

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that it has commenced its previou...

1 year ago - Business Wire

Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

1 year ago - Business Wire